Listed by the USPTO as CHENG, KAREN
Tech Center 1600 • Art Units: 1621 1622 1623 1626 1629
This examiner grants 76% of resolved cases
CHENG, KAREN works in tech center 1600 and art unit 1621, with 698 resolved cases. The allowance rate is 76.4%, and the median time to allowance is 774 days. The interview lift is 26.6%, supporting interviews as a potentially useful component of prosecution strategy.
The company record includes Boehringer Ingelheim International GmbH, AbbVie Inc., and BASF SE. The leading firms are Abel Schillinger, LLP, ARENTFOX SCHIFF LLP, and Bryan Cave Leighton Paisner LLP (DC). The combination of a favorable allowance rate and shorter median timeline supports active, structured prosecution planning.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18700748 | TRPC6 INHIBITORY COMPOUNDS FOR TREATING SEPSIS | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18268673 | PESTICIDAL MIXTURES | Final Rejection | BASF SE |
| 18562243 | APT1 and APT2 Inhibitors and Uses Thereof | Non-Final OA | Cornell University |
| 18008648 | PREPARATION METHOD OF ACRYLONITRILE DIMER | Non-Final OA | LG CHEM, LTD. |
| 18287809 | COMBINATION MEDICINE FOR PREVENTING/TREATING DYSLIPIDEMIA OR CARDIOVASCULAR DISEASE | Final Rejection | KOWA COMPANY, LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy76.4% of resolved applications examined by Karen Cheng were allowed (698 resolved cases), compared with 46.0% across Art Unit 1621 over the last five years.
This examiner's interview lift is +26.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Karen Cheng took 774 days on average from filing to allowance.
Karen Cheng examines applications in Art Unit 1621 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
